Title: MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy

Abstract

Abstract Glioblastoma (GB) is the most aggressive and common form of primary brain tumor, characterized by fast proliferation, high invasion, and resistance to current standard treatment. The average survival rate post-diagnosis is only of 14.6 months, despite the aggressive standard post-surgery treatment approaches of radiotherapy concomitant with chemotherapy with temozolomide. Altered cell metabolism has been identified as an emerging cancer hallmark, including in GB, thus offering a new target for cancer therapies. On the other hand, abnormal expression levels of miRNAs, key regulators of multiple molecular pathways, have been correlated with pathological manifestations of cancer, such as chemoresistance, proliferation, and resistance to apoptosis. In this work, we hypothesized that gene therapy based on modulation of a miRNA with aberrant expression in GB and predicted to target crucial metabolic enzymes might impair tumor cell metabolism. We found that the increase of miR-144 levels, shown to be downregulated in U87 and DBTRG human GB cell lines, as well as in GB tumor samples, promoted the downregulation of mRNA of enzymes involved in bioenergetic pathways, with consequent alterations in cell metabolism, impairment of migratory capacity, and sensitization of DBTRG cells to a chemotherapeutic drug, the dichloroacetate (DCA). Taken together, our findings provide evidence thatmore » the miR-144 plus DCA combined therapy holds promise to overcome GB-acquired chemoresistance, therefore deserving to be explored toward its potential application as a complementary therapeutic approach to the current treatment options for this type of brain tumor.« less

Authors:

Cardoso, Ana M. S.  ^[1];

• Search DOE PAGES for author "Cardoso, Ana M. S."
• Search DOE PAGES for ORCID "0000-0002-1629-4782"

Sousa, Madalena ^[2]; Morais, Catarina M. ^[2]; Oancea-Castillo, Liliana R. ^[3]; Régnier-Vigouroux, Anne ^[3]; Rebelo, Olinda ^[4]; Tão, Hermínio ^[5]; Barbosa, Marcos ^[6]; Pedroso, Maria C. de Lima ^[7]; Jurado, Amália S. ^[2]

---

+ Show Author Affiliations

1. Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal, Institute for Interdisciplinary Research of the University of Coimbra, 3030-789 Coimbra, Portugal
2. Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal, Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3000-456 Coimbra, Portugal
3. Institute for Developmental Biology and Neurobiology, Johannes Gutenberg University of Mainz, 55128 Mainz, Germany
4. Neuropathology Laboratory, Neurology Service, University Hospital of Coimbra, 3004-561 Coimbra, Portugal
5. Neurosurgery Service, University Hospital of Coimbra, 3004-561 Coimbra, Portugal
6. Neurosurgery Service, University Hospital of Coimbra, 3004-561 Coimbra, Portugal, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
7. Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal

Publication Date:

Tue May 14 00:00:00 EDT 2019

Sponsoring Org.:

USDOE Office of Energy Efficiency and Renewable Energy (EERE), Transportation Office. Fuel Cell Technologies Office

OSTI Identifier:

1563047

Grant/Contract Number:  

POCI-01-0145-FEDER-016390; POCI-01-0145-FEDER-007440

Resource Type:

Published Article

Journal Name:

Human Molecular Genetics

Additional Journal Information:

Journal Name: Human Molecular Genetics Journal Volume: 28 Journal Issue: 16; Journal ID: ISSN 0964-6906

Publisher:

Oxford University Press

Country of Publication:

United Kingdom

Language:

English